Donitriptan (INN) (code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed. It acts as a high-affinity, high-efficacy/near-full agonist of the 5-HT1B (pKi = 9.4–10.1; IA = 94%) and 5-HT1D receptors (pKi = 9.3–10.2; IA = 97%), and is among the most potent of the triptan series of drugs. Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.
- ↑ Dukat M (March 2001). "Donitriptan (Pierre Fabre)". Curr Opin Investig Drugs. 2 (3): 415–8. PMID 11575714.
- ↑ Perez M, Fourrier C, Sigogneau I, Pauwels PJ, Palmier C, Valentin JP, John GW, Halazy S (1995) Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: Potent agonists for 5-HT1D receptors. Journal of Medicinal Chemistry 38:3602–3607.
- ↑ Jes Olesen (2006). The Headaches. Lippincott Williams & Wilkins. pp. 470–. ISBN 978-0-7817-5400-2.
- ↑ John GW, Pauwels PJ, Perez M, et al. (July 1999). "F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine". J. Pharmacol. Exp. Ther. 290 (1): 83–95. PMID 10381763.
- ↑ Chas Bountra; Rajesh Munglani; William K. Schmidt (28 May 2013). Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. CRC Press. pp. 402–. ISBN 978-0-203-91125-9.
- ↑ W.W. Fleischhacker; D.J. Brooks (21 May 2003). Neuropsychopharmacology. Springer Vienna. pp. 38–. ISBN 978-3-211-83903-4.
- ↑ Stewart J. Tepper (2004). Understanding Migraine and Other Headaches. Univ. Press of Mississippi. pp. 118–. ISBN 978-1-60473-048-7.